Human Papillomavirus Vaccination Beyond Age 26: Evidence,Limitations,And Implications For Vaccination Policy

Abstract

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection globally and a major cause of anogenital and oropharyngeal cancers. Prophylactic HPV vaccination is most effective when administered before sexual debut and is routinely recommended for adolescents and young adults up to 26 years of age. However, ongoing HPV exposure throughout adulthood has prompted increasing interest in vaccination beyond this age group.

This narrative review examines evidence for HPV vaccination in adults aged 26 years and older from randomized trials, observational studies, and modeling analyses, with a focus on immunogenicity, clinical effectiveness, safety, and population-level impact. Data from randomized controlled trials, immunogenicity-bridging studies, and modeling analyses indicate that HPV vaccines remain highly immunogenic and safe in mid-adult adults and can prevent new infections with vaccine-covered HPV types. Nevertheless, the overall public health benefit and cost-effectiveness of extending routine vaccination to this age group are limited, largely due to prior HPV exposure and indirect protection conferred by established adolescent vaccination programs.

Overall, current evidence does not support routine HPV vaccination beyond age 26 at a population level. However, vaccination may still provide individual benefit in selected adults with ongoing or anticipated risk of new HPV exposure. These findings support a targeted, risk-based approach guided by shared clinical decision-making.

Keywords

human papillomavirus HPV vaccination adult vaccination mid-adult adults immunogenicity cost-effectiveness vaccination policy

Introduction

Human papillomavirus (HPV) comprises more than 200 subtypes and represents the most common sexually transmitted infection in the United States.¹ Infection is associated with a broad clinical spectrum, ranging from benign epithelial lesions such as warts to premalignant intraepithelial disease. Persistent infection with high-risk oncogenic genotypes, particularly HPV-16 and HPV-18, is a well-established cause of cancers of the cervix, anus, penis, vagina, vulva, and oropharynx. Screening strategies allow early detection of precancerous lesions, while barrier methods, including condoms and dental dams, may partially reduce viral transmission.

Vaccination represents the cornerstone of primary prevention of HPV-related disease. The nonavalent HPV vaccine has demonstrated high efficacy in preventing high-grade cervical precancerous lesions and is optimally administered at 11–12 years of age, using a two-dose schedule when administered before 15 years of age or a three-dose regimen in immunocompromised individuals.¹ In 2019, routine HPV vaccination was recommended for all individuals aged 9–26 years in the United States, with vaccination beyond this age guided by risk-based vaccination counseling. Since its initial approval in 2006 for females, age-based eligibility and dosing recommendations, particularly for males, have evolved considerably over time.²

Despite these recommendations, HPV exposure and acquisition continue throughout adulthood, raising important questions regarding the role, benefits, and limitations of vaccination beyond the routinely recommended age range. This review examines the evidence supporting HPV vaccination in adults older than 26 years and suggests that, while not appropriate as a universal strategy, vaccination in this population may have a limited clinical role, guided by individual risk rather than age-based criteria. In this review, the term mid-adult adults refer to individuals aged approximately 27–45 years, consistent with current vaccination policy discussions.

The objective of this review is to synthesize evidence on the immunogenicity, clinical effectiveness, safety, and cost-effectiveness of HPV vaccination beyond age 26, and to translate these findings into a clinically applicable risk-based framework for individualized vaccination decisions in adults.

Methods

This study is a structured narrative review using systematic search and screening methods to enhance transparency and reproducibility, but without formal systematic review synthesis or PRISMA reporting.

A comprehensive literature search was conducted in PubMed/MEDLINE and Embase for studies published between 1 January 2005 and 1 January 2025. The search combined controlled vocabulary (MeSH and Emtree terms) and free-text terms using Boolean operators. The full search strategies for PubMed/MEDLINE and Embase, including all keywords and controlled vocabulary terms, are provided in Appendix 1 to ensure transparency and reproducibility. The core search strategy included terms related to HPV, vaccination, adult populations, immunogenicity, clinical effectiveness, safety, cost-effectiveness, and policy. Search strategies were adapted to each database. Reference lists of included studies, relevant systematic reviews, randomized trials, and major guidelines were also screened to identify additional eligible publications.

Studies were included if they evaluated HPV vaccination in adults aged 27 years or older and reported outcomes related to immunogenicity, clinical effectiveness, safety, cost-effectiveness, or policy implications. Eligible study designs included randomized controlled trials, observational cohort studies, immunogenicity studies, and economic modeling analyses. Studies limited to adolescent populations, therapeutic vaccines, animal or in vitro research, and non-original publications were excluded.

All records were imported into a reference management system and duplicates removed. Two independent reviewers screened titles, abstracts, and full-text articles for eligibility, with disagreements resolved by discussion or consultation with a third reviewer. Study selection followed predefined eligibility criteria to reduce selection bias. The number of records identified, screened, assessed at full-text review, and included in the final synthesis is reported in the results section.

Data were extracted independently by two reviewers using a standardized framework capturing study design, population characteristics, age range, vaccine type, outcomes, and key findings. Given the substantial heterogeneity across studies, a qualitative narrative synthesis was performed, with studies organized thematically into immunogenicity, clinical effectiveness, safety, cost-effectiveness, and policy domains.

Formal meta-analysis was not conducted due to methodological heterogeneity. Because of substantial heterogeneity in study designs and outcomes, a formal risk-of-bias tool was not applied. Instead, study quality was appraised qualitatively based on study design hierarchy, sample size, methodological transparency, and consistency of findings across studies. Greater interpretive weight was assigned to randomized controlled trials, large cohort studies, and economic models with clearly reported assumptions.

A total of 7,220 records were identified from PubMed/MEDLINE (n = 4,453) and Embase (n = 2,767) searches conducted between 1 January 2005 and 1 January 2025. After removal of duplicates, records were screened for eligibility. Full-text articles were assessed, and 14 studies meeting the predefined inclusion criteria were included in the final qualitative synthesis. The study selection process is summarized in Figure 1.

Figure 1.

Study selection flow diagram

As this was a structured narrative review of published literature, ethical approval was not required.

Natural History of HPV Infection

Human papillomavirus (HPV) is a small, non-enveloped double-stranded DNA virus with oncogenic potential mediated primarily by the viral oncoproteins E6 and E7, which promote degradation of p53 and inactivation of the retinoblastoma (pRB) protein, leading to uncontrolled cellular proliferation. Most HPV infections are asymptomatic and transient, with immune-mediated clearance occurring within one to two years. Only a minority of infections persist and progress to premalignant intraepithelial lesions, a process strongly influenced by viral load and infection with high-risk genotypes, including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, which are disproportionately associated with high-grade precancerous lesions and invasive malignancies.³

HPV exposure is not limited to early adulthood. Acquisition of new sexual partners later in life, reinfection with different genotypes, and reactivation of latent infection contribute to ongoing risk across the lifespan.³ Epidemiologic studies demonstrate a second peak in HPV prevalence among mid-adult adults, highlighting that increasing age does not equate to protection from HPV exposure or oncogenic risk.⁴ Moreover, clearance of HPV infection does not reliably confer durable protective immunity, allowing reinfection with different oncogenic genotypes throughout adulthood.²

Immunologic Rationale for HPV Vaccination in Adults Aged 27–45 Years

HPV infection activates both innate and adaptive immune responses, involving epithelial keratinocytes and Langerhans cells, as well as natural killer cells and HPV-specific B- and T-cell responses.⁵ However, these immune mechanisms are often insufficient to achieve durable viral clearance. HPV infects and replicates exclusively within epithelial keratinocytes, which are relatively distant from lymphoid immune centers and have limited antigen-presenting capacity. In addition, the viral life cycle is tightly linked to keratinocyte differentiation and proceeds without cell lysis or significant inflammation, enabling immune evasion and persistence in a subset of infected individuals.⁶

As a result, natural HPV infection does not induce broad or durable protective immunity. Antibody responses following natural infection are typically weak, delayed, and largely type-specific, with a particularly limited protective effect observed in men. In contrast, prophylactic HPV vaccines are based on self-assembled virus-like particles derived from the major capsid protein and elicit robust humoral immune responses. Vaccination induces substantially higher and more durable neutralizing antibody titers than those generated through natural infection. These antibodies act early at the epithelial surface to block viral entry and prevent the establishment of infection.

Because vaccine-induced immunity is prophylactic and genotype-specific, prior exposure to one HPV type does not preclude protection against other oncogenic genotypes included in the vaccine. Consequently, mid-adult adults with ongoing risk of HPV acquisition, such as those with new or multiple sexual partners or incomplete prior exposure to vaccine-covered types, may still derive meaningful benefit from HPV vaccination despite previous exposure to HPV.^2,7

Clinical Evidence for HPV Vaccination in Adults Aged 27–45 Years

Evidence supporting HPV vaccination in adults aged 27–45 years is derived primarily from randomized clinical trials in women and immunogenicity-bridging studies in men. In the FUTURE III program, women vaccinated between 27 and 45 years of age demonstrated sustained protection against HPV 6/11/16/18–related outcomes over long-term follow-up, with no breakthrough cases of vaccine-type high-grade cervical disease or genital warts observed in the per-protocol population. Vaccine-induced antibodies persisted for nearly a decade, supporting the durability of immune protection.

Additional randomized trial data in women aged 24–45 years further confirm high vaccine efficacy against persistent infection and HPV-related disease, exceeding 85% among those naïve to vaccine HPV types at vaccination. Importantly, partial protection was also observed in women with prior serologic evidence of HPV exposure but no active infection at baseline, indicating that previous exposure does not preclude benefit, as vaccination protects against HPV types not yet acquired. Across studies, vaccination was well tolerated, with no serious vaccine-related adverse events reported.^8-10

Among men aged 27–45 years, direct clinical efficacy endpoints have not been assessed. However, immunogenicity-bridging analyses demonstrate that antibody responses in adults aged 27–45 years are comparable to those observed in younger male cohorts in whom clinical efficacy has been established, allowing efficacy to be inferred in this population.⁸

However, interpretation is limited by heterogeneity in baseline HPV exposure, sexual behavior, and follow-up duration across studies. From a clinical interpretation perspective, immunogenicity should be interpreted cautiously as a surrogate endpoint, as antibody titers do not directly define a protective threshold for prevention of persistent infection or malignancy. The correlation between vaccine-induced antibody levels and long-term clinical protection in adults aged 27–45 years remains incompletely established, particularly in individuals with prior HPV exposure. In addition, duration of protection beyond the first decade after vaccination in older age groups is based primarily on extrapolation rather than direct longitudinal evidence.

Economic modeling studies evaluating the extension of HPV vaccination into mid-adult adults suggest that, although vaccination of adults aged 27–45 years can prevent additional HPV-related cancers and genital warts, the population-level benefit is modest compared with vaccination at younger ages. In a U.S. cost-effectiveness analysis using two independent microsimulation models, extending vaccination beyond age 26 years was associated with high incremental cost-effectiveness ratios exceeding commonly accepted willingness-to-pay thresholds, even when noncervical cancers were included. These findings reflect preexisting HPV exposure, declining rates of new infection with age, indirect protection from established adolescent vaccination programs, and the long latency between infection and cancer development. Consequently, while adult vaccination may offer meaningful individual benefit in selected cases, routine population-wide vaccination of adults aged 27–45 years is unlikely to be cost-effective in the U.S. setting.⁹

These findings are not fully consistent across studies, likely reflecting differences in model assumptions, population HPV prevalence, and vaccine uptake scenarios. This heterogeneity underscores the need to move beyond age-based recommendations and focus instead on identifying adults who are most likely to benefit from HPV vaccination.

Cost-effectiveness estimates are highly sensitive to several key assumptions, including history of HPV exposure, age at vaccination, sexual behavior patterns, vaccine pricing, and background screening practices. Models consistently demonstrate that vaccination earlier in life yields substantially greater health gains per cost unit than vaccination initiated in mid-adult adults. In addition, increasing adolescent vaccine coverage amplifies herd protection and further reduces the incremental benefit of vaccinating mid-adult adults.

Identifying Mid-adult Adults Who May Benefit From HPV Vaccination

HPV vaccination in adults aged 27–45 years is not recommended as a universal strategy but may be considered using individualized vaccine counseling for individuals who are likely to benefit from protection against new HPV infections.¹¹ Epidemiologic and longitudinal cohort studies demonstrate that acquisition of new HPV infections continues throughout adulthood and is closely linked to ongoing sexual exposure, particularly the presence of new or multiple sexual partners.¹² Men remain at lifelong risk of HPV acquisition and do not consistently develop durable protective immunity following natural infection, leaving them susceptible to vaccine-preventable HPV types.¹² HPV immunity is predominantly type-specific, and prior infection with one genotype does not confer cross-protection against other oncogenic types included in current vaccines.⁷ Natural infection also induces variable and often incomplete long-term immunity, particularly in men, where reinfection with multiple HPV genotypes has been documented.¹² At present, no validated clinical test is available to determine type-specific susceptibility or to guide individualized vaccination based on prior exposure status.¹¹

Adults anticipating future sexual exposure, such as those entering new relationships after divorce, separation, or widowhood, may benefit from vaccination. In contrast, individuals in long-term, mutually monogamous relationships are unlikely to acquire new HPV infections.

Selected individuals with immunocompromising conditions may also be considered for vaccination, recognizing that vaccine effectiveness may be reduced and decisions should be individualized.

Because HPV vaccines are prophylactic and do not treat existing infection or HPV-related disease, their benefit is greatest in adults who remain at risk for acquiring new HPV types. Accordingly, HPV vaccination beyond age 26 should be targeted toward individuals with ongoing or anticipated risk of new HPV exposure rather than applied as a population-wide strategy. Key clinical scenarios in which HPV vaccination beyond age 26 may offer individual benefit are summarized in Table 1.^11,12

Table 1.

Clinical Scenarios in Which Adults May Benefit From HPV Vaccination Beyond Age 26^11,12

Clinical situation	Rationale
New or multiple sexual partners	Ongoing risk of acquiring new HPV types
Re-entering dating (divorce, separation, widowhood)	Increased likelihood of new HPV exposure
Non–mutually monogamous partnerships	Risk persists despite a stable relationship
Men	Lack of durable natural immunity; lifelong acquisition risk
Limited prior exposure to HPV	Susceptibility to vaccine-covered types remains
Selected immunocompromised adults	Higher persistence risk; individualized benefit

Figure 2 summarizes a risk-based clinical framework for HPV vaccination in adults aged 27–45 years.

Figure 2.

Risk-based clinical algorithm for shared decision-making on HPV vaccination beyond age 26

Practical clinical scenarios may help guide shared decision-making in clinical practice. For example, a 35-year-old individual entering new sexual relationships after divorce or separation may have an ongoing risk of HPV exposure and could derive benefit from vaccination. Similarly, adults with multiple recent sexual partners or men who have sex with men may remain susceptible to vaccine-preventable HPV types despite prior exposure. In contrast, individuals in long-term mutually monogamous relationships are less likely to acquire new HPV infections and therefore may derive limited benefit from vaccination. These considerations illustrate how individualized risk assessment can inform HPV vaccination decisions in adults aged 27–45 years.

Clinical and Public Health Implications of Adult HPV Vaccination

HPV vaccination in adults older than 26 years differs fundamentally from adolescent vaccination strategies, as the primary benefit is individual protection against HPV types not previously acquired rather than broad population-level disease reduction. Vaccination decisions should therefore be guided by individualized assessment of future HPV exposure risk and integrated with established cervical cancer screening practices. From a public health perspective, routine vaccination of all adults beyond age 26 is unlikely to substantially reduce HPV-related disease burden because of previous exposure to HPV, lower rates of new infection with increasing age, and indirect protection from adolescent vaccination programs. Adult vaccination is therefore best viewed as a selective preventive strategy for individuals most likely to benefit.^9,11,13

However, the evidence base supporting HPV vaccination beyond age 26 remains heterogeneous, with variability in study populations, endpoints, and baseline susceptibility profile across trials and observational studies. Immunogenicity and short-to medium-term effectiveness remain favorable, but direct evidence of long-term cancer prevention in adults aged 27–45 years is limited, and cost-effectiveness estimates are highly sensitive to underlying assumptions. These uncertainties highlight the need for cautious interpretation when extrapolating individual-level benefits to broader policy recommendations.

Implementation in primary care settings may also be constrained by limited consultation time, competing preventive care priorities, variability in clinician familiarity with shared decision-making for adult vaccination, and potential inequities in access to preventive services across different populations.

In addition, access to adult vaccination may vary substantially according to healthcare coverage, vaccine cost, and availability of preventive services, potentially creating inequities in implementation. These barriers may disproportionately affect populations already at increased risk for HPV-related disease and should be considered when translating shared decision-making recommendations into routine practice.

Knowledge Gaps in Adult HPV Vaccination

Despite evidence supporting individual-level benefit, important limitations and unresolved questions remain regarding HPV vaccination in mid-adult adults. Randomized trials of HPV vaccination in adults were not designed to assess reductions in HPV-related cancers. In women older than 25 years, significant protection against high-grade cervical intraepithelial neoplasia (CIN2/3) was not consistently demonstrated. Because progression from HPV infection to malignancy often occurs over decades, direct evidence of cancer prevention following vaccination in mid-adult adults remains limited.¹⁴

In a phase II trial of men aged 27–45 years, HPV vaccination induced 100% seroconversion to all four vaccine types and was well tolerated, with antibody responses comparable to those observed in younger male cohorts in whom clinical efficacy has been demonstrated; however, the study was not designed to assess protection against persistent infection or clinical disease.¹⁵

Cost-effectiveness analyses suggest that HPV vaccination beyond routinely targeted adolescent and young adult groups provides limited population-level value, highlighting important constraints in extending vaccination to mid-adult adults. Estimates of public health impact vary widely across models and are highly sensitive to assumptions regarding earlier exposure to vaccine-covered HPV types, sexual behavior, vaccine pricing, screening practices, and uncertainties in the natural history of noncervical HPV-related cancers. These methodological dependencies represent key limitations, restricting the generalizability of findings across different populations and healthcare settings.¹⁶

Although increased clinician and patient awareness and broader use of clinical risk stratification may support HPV prevention efforts in adults aged 27–45 years, implementation in routine care remains challenging. The lack of validated tools to assess individual susceptibility, combined with time constraints, evolving evidence, and the complexity of communicating personalized risk–benefit information, may limit consistent uptake in real-world settings.¹⁷

Much of the current evidence relies on surrogate immunologic endpoints rather than direct reductions in persistent infection, precancerous lesions, or HPV-related cancers, particularly in men and older adults. These limitations highlight the need for long-term observational studies and clearer clinical frameworks to support individualized vaccination decisions in adults.

Limitations

This review has several limitations. First, the narrative design does not follow formal systematic review methodology and may therefore be subject to selection bias. Although major biomedical databases were searched, relevant studies published outside the selected databases or in non-English languages may not have been captured. Second, no formal risk-of-bias assessment was performed, and the included studies vary in design and methodological quality. Third, the evidence base for HPV vaccination in adults remains heterogeneous, with limited long-term data on cancer prevention outcomes. These limitations should be considered when interpreting the conclusions of this review.

Conclusion

In conclusion, HPV vaccination beyond age 26 is not supported as a universal public health strategy due to prior exposure, lower rates of new HPV acquisition with increasing age, and indirect protection from adolescent vaccination programs. However, selected adults with ongoing or anticipated risks of new HPV exposure may still benefit at the individual level. A risk-based, shared clinical decision-making approach is therefore most appropriate in this age group.

Footnotes

Author Note

All authors critically revised the manuscript and approved the final version.

ORCID iD

Akel Azzi

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Appendix

References

Quinlan

. Human papillomavirus: screening, testing, and prevention. Am Fam Physician. 2021;104(2):152-159.

Laserson

Oliffe

Krist

Kelly

. HPV vaccine and college-age men: a scoping review. Am J Mens Health. 2020;14(6):1-12. doi:10.1177/1557988320973826.

de Sanjosé

Brotons

Pavón

. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13. doi:10.1016/j.bpobgyn.2017.08.015.

Chow

EPF

Fairley

. A second peak in genital warts in later life suggests that behavioural factors explain a second peak in human papillomavirus prevalence in older women. Sex Health. 2015;12(4):277-278. doi:10.1071/SH15097.

Kiamba

Goodier

Clarke

. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297. doi:10.3389/fimmu.2025.1591297.

Stanley

. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16-S22. doi:10.1016/j.vaccine.2005.09.002.

Schiller

Lowy

. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681-692. doi:10.1038/nrmicro2872.

Maldonado

Plata

Gonzalez

, et al. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years. Hum Vaccin Immunother. 2022;18(5):2078626. doi:10.1080/21645515.2022.2078626.

Kim

Simms

Killen

, et al. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: a cost-effectiveness analysis. PLoS Med. 2021;18(3):e1003534. doi:10.1371/journal.pmed.1003534.

10.

Castellsagué

Muñoz

Pitisuttithum

, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105(1):28-37. doi:10.1038/bjc.2011.185.

11.

Meites

Szilagyi

Chesson

Unger

Romero

Markowitz

. Human papillomavirus vaccination for adults aged 27 through 45 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698-702.

12.

Giuliano

Lee

Fulp

, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932-940. doi:10.1016/S0140-6736(10)62342-2.

13.

Schiffman

Castle

Jeronimo

Rodriguez

Wacholder

. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907. doi:10.1016/S0140-6736(07)61416-0.

14.

Arbyn

Rousta

Bruni

Schollin Ask

Basu

. Linkage of individual-patient data confirms protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. JNCI J Natl Cancer Inst. 2024;116(6):775-778. doi:10.1093/jnci/djae042.

15.

Giuliano

Isaacs-Soriano

Torres

, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years): the MAM Study. Vaccine. 2015;33(42):5640-5646. doi:10.1016/j.vaccine.2015.08.072.

16.

Chesson

Meites

Ekwueme

Saraiya

Markowitz

. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: estimates from a simplified transmission model. Vaccine. 2020;38(49):8032-8039. doi:10.1016/j.vaccine.2020.10.028.

17.

King

Lewnard

Niccolai

. Clinical and public health considerations for HPV vaccination in midadulthood: a narrative review. Open Forum Infect Dis. 2023;10(1):ofad004. doi:10.1093/ofid/ofad004.